Tandem Diabetes Care received FDA clearance for the Android version of its Tandem Mobi mobile app, allowing Android users to manage insulin delivery through its automated insulin pump system. The integration of Tandem's t:slim X2 with the Abbott FreeStyle Libre 3 Plus sensor was highlighted as a significant advancement in enhancing device connectivity. The company projects .2 billion in revenue and .4 million in earnings by 2028, requiring an annual revenue growth rate of 7.5% and an earnings increase from -5.5 million. Community fair value estimates for Tandem Diabetes Care range from .64 to .72.